Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-blind, Intra-individual Comparison, Proof-of-concept Trial of Topical AC-203 in Patients With Inherited Epidermolysis Bullosa

Trial Profile

A Double-blind, Intra-individual Comparison, Proof-of-concept Trial of Topical AC-203 in Patients With Inherited Epidermolysis Bullosa

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Jan 2019

At a glance

  • Drugs Diacerein (Primary)
  • Indications Epidermolysis bullosa
  • Focus Proof of concept; Therapeutic Use
  • Sponsors TWi Biotechnology
  • Most Recent Events

    • 22 Jan 2019 According to a TWi Biotechnology media release, enrollment was completed within 3 months in this trial.The company expects to report top-line results in second quarter of 2019. The trial results will help support TWIB's global development partner, Castle Creek Pharma (CCP), to extend the indication in both US and EU.
    • 16 Jan 2019 Status changed from recruiting to active, no longer recruiting.
    • 16 Nov 2018 Planned End Date changed from 1 Feb 2019 to 1 May 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top